Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

carbon C 11 erlotinib hydrochloride

The hydrochloride salt form of the quinazoline derivative erlotinib labeled with the positron-emitting isotope carbon C 11, with potential use in imaging. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Following exposure to this agent, EGFR expression status can be determined and EGFR overexpressing tumor cells can be visualized using positron emission tomography (PET) imaging. This may be useful in determining the tumor cell response to a particular EGFR kinase inhibitor in individual patients. EGFR, a receptor tyrosine kinase, is overexpressed in numerous cancer cell types, and plays a significant role in tumor cell progression.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:C11-erlotinib hydrochloride
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search